Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Awaiting development: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Area of interest
Area of interest
COVID-19 (10)
Type
(
1 selected
)
Type
Guidance (285)
Guidance programme
(
1 selected
)
Guidance programme
Diagnostics guidance (1)
Health technology evaluations (6)
Highly specialised technologies guidance (1)
Interventional procedures guidance (6)
Medical technologies guidance (5)
Technology appraisal guidance (285)
Apply filters
Showing 111 to 120 of 285
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483
Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491
Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376
Technology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990
Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190
Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469
Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949
Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Technology appraisal guidance
Previous page
1
…
10
11
Current page
12
13
14
…
29
Page
12
of
29
Next page
Results per page
10
25
50
All
Back to top